Skip to content

AOCI at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$112.15M-30.8%
Viatris logo
ViatrisVTRS
-$2.8B+2.5%
AMP
Amphastar PharmaceuticalsAMPH
-$5.74M+28.0%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$8K+147%

Other financials

Income statement

See full
Revenue$22.7M+184%
Operating income-$60.1M-61.8%
Net income-$60.6M-78.6%
EPS (diluted)-$0.61-74.3%

Balance sheet

See full
Cash & equivalents$24.3M-39.0%
Total debt$96.5M+132,122%
Total equity$61.3M-73.2%
Total assets$287.6M-12.1%

Cash flow

See full
Operating cash flow-$44.9M-10.3%
CapEx--100%
Free cash flow-$44.9M-10.1%

Valuation

See full
Market cap$796.41M-48.7%
Enterprise value$868.61M-42.6%
P/S8.1×-7.9×

Profitability

See full
Operating margin-204.5%
Net margin-200%-219pp
FCF margin-177.1%-206pp

Returns & leverage

See full
Return on equity-136.4%-144pp
Debt / equity1.6×+1.6×
Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s AOCI?
ARS Pharmaceuticals, Inc. (SPRY) reported AOCI of -$96K in Q1 2026.
How has ARS Pharmaceuticals, Inc.'s AOCI changed year-over-year?
ARS Pharmaceuticals, Inc.'s AOCI decreased by 233.3% year-over-year, from $72K to -$96K.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.